Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
modRNA influenza B challenge vaccine efficacy study
ISRCTN13559330Phase 2Completed
- Sponsor
- hVIVO
- Start
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of TIRV HA, influenza vaccine (cell-based) and sodium chloride in influenza (4 arms), sponsored by hVIVO. Primary endpoints: Area under the viral load-time curve (VLAUC) by qRT-PCR, Peak viral load (VLPEAK) by qRT-PCR and 2 more. Started Apr 2024; status: completed.
02
Drugs
TIRV HAinfluenza vaccine (cell-based)sodium chloride
03
Conditions
influenza
Beyond the preview
Go deeper on ISRCTN13559330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13559330.